Delcath Systems is a development stage pharmaceutical and medical device company focused on oncology. The company's proprietary system for chemosaturation is designed to administer high-dose chemotherapy to regions of the body under attack from cancer. Its initial focus is on the treatment of liver cancers.
The company today announced that Quintiles will provide a specialized team of medical science liasons (MSLs) to support of the launch of the Hepatic CHEMOSAT Delivery for the treatment of liver cancers in Europe, including the nations of France, Germany, Netherlands, Spain, Italy, Ireland, and the UK.
Quintiles will also provide medical communication services. The MSL team, comprised of doctors, nurses, pharmacologists, and cancer specialists will draw on their understanding of the European healthcare environment and use their relationships with key opinion leaders to educate local oncologists and hepatology specialists on the clinical benefits of CHEMOSAT.
Delcath feels that it needs the full support of Quintiles specialists because of the very complex nature of the European healthcare industry. The best way for their product to gain acceptance in Europe is to attain help in navigating the local healthcare systems from medical specialists, particularly in oncology, in the region.
For additional information about Delcath Systems and CHEMOSAT, please visit the company's website at www.delcath.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html